JX10 / Biogen, TMS Co, CORXEL - LARVOL DELTA

A Novel Thrombolytic with Anti-inflammatory Properties (JX10) Improves Neurological Outcomes in Acute Lacunar Infarct up to 12 hours After Onset (ISC 2025) - "JX10 improved functional outcome in patients who presented with lacunar infarct, as measured by mRS at day 90 vs placebo. Findings support further testing of JX10 in larger and broader patient populations."

Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Anti-Inflammatory Thrombolytic JX10 (TMS-007) in Late Presentation of Acute Ischemic Stroke. (PubMed, Stroke) - "JX10 was well tolerated and may expand the acute ischemic stroke therapeutic window as a novel thrombolytic agent. URL: https://rctportal.niph.go.jp/en; Unique identifier: jRCT2080223786."

Clinical • Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

DESIGN OF DAISY, A TWO-PART, PHASE 2B, PLACEBO-CONTROLLED RANDOMISED TRIAL OF THE EFFICACY AND SAFETY OF BIIB131 ADMINISTERED 4.5–24 HOURS AFTER ISCHAEMIC STROKE (ESOC 2023) - "BIIB131 (TMS-007) uniquely induces thrombolysis by promoting plasminogen-fibrin binding with potential anti-inflammatory properties... Data from DAISY will determine the optimal dose, efficacy and safety of BIIB131 4.5– 24 hours after LKW in patients with AIS."

Clinical • P2b data • Cardiovascular • Ischemic stroke

A first-in-human study of the anti-inflammatory profibrinolytic TMS-007, an SMTP family triprenyl phenol. (PubMed, Br J Clin Pharmacol) - "TMS-007 is generally well tolerated and exhibits favorable pharmacokinetic profiles that warrant further clinical development."

Journal • P1 data • Cardiovascular • Hematological Disorders • Ischemic stroke

Results From A Phase 2a Study Of TMS-007, An SMTP Family Anti-inflammatory Prothrombolytic, On Patients With Acute Ischemic Stroke Up To 12 Hours After Onset (ISC 2022) - "TMS-007 may expand the treatment time window for the treatment of AIS. Due to the small study size, more data on efficacy is warranted in patients with visible occlusion."

Clinical • P2a data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Ischemic stroke • Thrombosis

"$BIIB pretty much keeps on pushing their readouts Jan 2020 July 2020 BIIB111 end 2020 H1 2021 BIIB054 H2 2020 H1 2021 TMS 007 end 2020 H1 2021" (@BursatilBiotech)